期刊
INTERNATIONAL REVIEWS OF IMMUNOLOGY
卷 30, 期 2-3, 页码 150-182出版社
TAYLOR & FRANCIS INC
DOI: 10.3109/08830185.2011.572210
关键词
whole tumor cell vaccine; ovarian carcinoma; immunogenicity; adjuvants; cytokines; Toll-like receptor agonists
类别
资金
- NIH [P50-CA083638]
- Ovarian Cancer Research Fund
- Ovarian Cancer Immunotherapy Initiative
Whole tumor cell lysates can serve as excellent multivalent vaccines for priming tumor-specific CD8(+) and CD4(+) T cells. Whole cell vaccines can be prepared with hypochlorous acid oxidation, UVB-irradiation and repeat cycles of freeze and thaw. One major obstacle to successful immunotherapy is breaking self-tolerance to tumor antigens. Clinically approved adjuvants, including Montanide (TM) ISA-51 and 720, and keyhole-limpet proteins can be used to enhance tumor cell immunogenicity by stimulating both humoral and cellular anti-tumor responses. Other potential adjuvants, such as Toll-like receptor agonists (e. g., CpG, MPLA and PolyI:C), and cytokines (e.g., granulocyte-macrophage colony stimulating factor), have also been investigated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据